Study guide
10.1 Altered Pharmacokinetics in Critically Ill Patients
Board Certified Critical Care Pharmacist Study Guide Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pathophysiology and Recognition of Critical Illness
1.1 Pathophysiology of Shock and Sepsis 1.2 Respiratory Failure and ARDS Pathophysiology 1.3 ICU-Acquired Weakness and Post-Intensive Care Syndrome 1.4 Chronic Disease States and Risk Factors for Critical Illness
2 Chapter 2: Medical Devices and Circulatory Support
2.1 Hemodynamic Monitoring and Interpretation 2.2 Mechanical Circulatory Support 2.3 Mechanical Ventilation Modes and Settings 2.4 Continuous Renal Replacement Therapy 2.5 Lines, Tubes, and Drains in Critical Care
3 Chapter 3: Fluid, Electrolyte, and Acid-Base Management
3.1 Resuscitation Fluids: Crystalloids vs. Colloids 3.2 Electrolyte Disorders in the ICU 3.3 Acid-Base Disorders and Interpretation
4 Chapter 4: Vasoactive and Inotropic Therapy in Shock
4.1 Vasopressors in Distributive Shock 4.2 Inotropes and Vasopressors in Cardiogenic and Obstructive Shock
5 Chapter 5: Sedation, Analgesia, and Delirium (PADIS)
5.1 Pain and Analgesia in the ICU 5.2 Sedation Strategies and Medication Selection 5.3 Delirium Assessment, Prevention, and Treatment 5.4 Neuromuscular Blockade in Critical Illness
6 Chapter 6: Cardiovascular Emergencies
6.1 Acute Coronary Syndromes in ICU Patients 6.2 Acute Decompensated Heart Failure 6.3 Hypertensive Emergencies and Arrhythmias
7 Chapter 7: Pulmonary and Infectious Diseases in the ICU
7.1 Severe Sepsis and Septic Shock Antimicrobial Selection 7.2 Pharmacotherapy for Mechanical Ventilation and ARDS 7.3 Severe Infections in the ICU
8 Chapter 8: Neurocritical Care
8.1 Ischemic and Hemorrhagic Stroke Management 8.2 Intracranial Hypertension and Brain Edema 8.3 Status Epilepticus and Sedation in Brain Injury
9 Chapter 9: Toxicology, Endocrine, and Hematologic Emergencies
9.1 Toxicology and Antidote Therapy in the ICU 9.2 Endocrine Emergencies 9.3 Hematologic Emergencies, Anticoagulant Reversal, and Transfusions 9.4 Gastrointestinal and Hepatic Emergencies in the ICU 9.5 Dermatologic and Immunologic Conditions in the ICU 9.6 Trauma, Burns, Supportive Care, and End-of-Life Pharmacotherapy
10 Chapter 10: Special Populations, Pharmacokinetics, and Nutrition
10.1 Altered Pharmacokinetics in Critically Ill Patients 10.2 Therapeutic Drug Monitoring in the ICU 10.3 Nutrition Support: Enteral vs. Parenteral
11 Chapter 11: Quality, Safety, and Clinical Guidelines
11.1 Medication Safety and Error Prevention in the ICU 11.2 Antimicrobial Stewardship and Infection Prevention 11.3 Implementation of Clinical Practice Guidelines 11.4 Healthcare Regulations, Standards, and Drug Interactions
12 Chapter 12: Practice Management, Biostatistics, and Evidence-Based Medicine
12.1 ICU Formulary Management and Cost-Effectiveness 12.2 Biostatistics and Literature Evaluation 12.3 Clinical Trial Interpretation in Critical Care 12.4 Professional Development, Precepting, and ICU Pharmacy Services 12.5 Alternative ICU Delivery Models and Disaster Healthcare Management
13 Chapter 13: Treatment Planning and Care Coordination
13.1 Goals of Care, Perioperative Care, and Transitions of Care 13.2 Medication Delivery Routes and Devices in Critical Illness 13.3 Social Determinants of Health and Patient/Caregiver Education
10.1 Altered Pharmacokinetics in Critically Ill Patients
Key Takeaways Explain This Topic AI
Critical illness significantly alters the absorption, distribution, metabolism, and excretion (ADME) of many medications, requiring vigilant dosage adjustments.
Increased capillary permeability and aggressive fluid resuscitation lead to an increased volume of distribution (Vd) for hydrophilic drugs.
Augmented renal clearance (ARC) can occur in hyperdynamic states, necessitating higher doses of renally cleared medications like beta-lactam antibiotics.
Organ dysfunction, such as acute kidney injury (AKI) or hepatic failure, reduces drug clearance, increasing the risk of toxicity.
Altered protein binding, particularly hypoalbuminemia, affects the free (active) fraction of highly protein-bound drugs.
Last updated: July 2026
Altered Pharmacokinetics in Critically Ill Patients
Quick Answer: Critical illness drastically changes how the body processes drugs. Key alterations include increased volume of distribution (Vd) due to fluid shifts, unpredictable drug absorption, altered protein binding from hypoalbuminemia, and fluctuating organ function affecting metabolism and excretion. Clinicians must continuously adjust dosing regimens based on a patient's dynamic clinical status.
Critically ill patients experience complex physiological changes that profoundly impact the pharmacokinetics (PK) of medications. The classic ADME model (Absorption, Distribution, Metabolism, and Excretion) is often distorted, making standard dosing regimens inadequate or unsafe. Recognizing and anticipating these PK alterations is a fundamental skill for the BCCCP pharmacist.
Absorption Alterations
Drug absorption in the ICU is notoriously unpredictable, particularly for enteral and extravascular routes.
Enteral Absorption
Several factors compromise the enteral absorption of medications:
Delayed Gastric Emptying and Ileus: Common in trauma, sepsis, and following surgery, reducing the rate and extent of absorption.
Vasopressor Use: High doses of vasopressors (e.g., norepinephrine, epinephrine) cause splanchnic vasoconstriction, shunting blood away from the gastrointestinal (GI) tract and diminishing drug absorption.
Enteral Nutrition Interactions: Continuous enteral feeds can bind to certain drugs (e.g., phenytoin, fluoroquinolones, levothyroxine), preventing their absorption. Often, tube feeds must be held before and after drug administration.
Altered Gastric pH: The use of stress ulcer prophylaxis (proton pump inhibitors, H2-receptor antagonists) increases gastric pH, which can impair the absorption of drugs requiring an acidic environment (e.g., itraconazole, ketoconazole).
Subcutaneous and Intramuscular Absorption
In shock states, peripheral hypoperfusion and edema severely reduce the absorption of subcutaneously and intramuscularly administered medications. Consequently, the intravenous (IV) route is preferred to ensure reliable drug delivery.
Volume of Distribution (Vd) Changes
The volume of distribution represents the theoretical volume into which a drug disperses. In critical illness, Vd is highly variable.
Fluid Resuscitation and Capillary Leak
Conditions like sepsis and severe burns trigger systemic inflammation, leading to endothelial dysfunction and increased capillary permeability (often termed "capillary leak" or "third spacing"). Furthermore, these patients typically receive massive fluid resuscitation.
Hydrophilic Drugs: Drugs that are water-soluble (e.g., beta-lactams, aminoglycosides, vancomycin) distribute extensively into this expanded extracellular fluid volume. This results in a significantly increased Vd, meaning that a larger initial loading dose is required to achieve therapeutic plasma concentrations.
Lipophilic Drugs: The Vd of lipid-soluble drugs (e.g., fluoroquinolones, macrolides, most sedatives) is less affected by fluid shifts, as they primarily distribute into adipose and other tissues rather than extracellular fluid.
Altered Protein Binding
Many drugs bind to plasma proteins, primarily albumin (for acidic drugs) and alpha-1-acid glycoprotein (AAG) (for basic drugs). Only the "free" or unbound fraction of a drug is pharmacologically active and available for clearance.
Hypoalbuminemia
Hypoalbuminemia is ubiquitous in the ICU due to decreased synthesis, increased degradation, and capillary leak.
When albumin levels drop, the free fraction of highly protein-bound drugs (e.g., phenytoin, valproic acid, ceftriaxone) increases.
While the total drug concentration may appear normal or low, the free (active) concentration might be therapeutic or even toxic. This necessitates monitoring free drug levels when possible or adjusting interpretations of total levels.
Elevated Alpha-1-Acid Glycoprotein (AAG)
AAG is an acute-phase reactant whose levels rise during stress, inflammation, and trauma.
Elevated AAG can increase the binding of basic drugs (e.g., lidocaine, propranolol, fentanyl), potentially decreasing their free, active fraction and dampening their clinical effect.
Metabolism and Hepatic Clearance
Hepatic metabolism relies on intrinsic liver enzyme activity and hepatic blood flow.
Decreased Hepatic Blood Flow: Conditions like congestive heart failure, shock, or the use of high-dose vasopressors reduce blood flow to the liver. This impairs the clearance of "high-extraction ratio" drugs (e.g., propofol, lidocaine, fentanyl), whose metabolism is flow-dependent.
Hepatocellular Dysfunction: Acute liver failure, hypoxic hepatitis (shock liver), or severe systemic inflammation can downregulate cytochrome P450 (CYP) enzymes, reducing the clearance of "low-extraction ratio" drugs (e.g., phenytoin, warfarin), which depend on intrinsic enzyme activity.
Therapeutic Hypothermia: Targeted temperature management (TTM) can significantly decrease CYP enzyme activity, prolonging the half-life of many medications, notably sedatives and paralytics.
Excretion and Renal Clearance
Renal function in the ICU is highly dynamic, fluctuating between hyperfiltration and failure.
Augmented Renal Clearance (ARC)
ARC is defined as a creatinine clearance (CrCl) > 130 mL/min/1.73 m². It is common in younger patients, trauma victims, burn patients, and those with early sepsis. The hyperdynamic state increases cardiac output and renal blood flow, enhancing glomerular filtration. ARC leads to the rapid elimination of renally cleared drugs (e.g., beta-lactam antibiotics, levetiracetam), often resulting in subtherapeutic concentrations. Higher doses or more frequent administration (or continuous infusions) are required.
Acute Kidney Injury (AKI)
Conversely, AKI is a frequent complication in the ICU. Decreased glomerular filtration rate (GFR) reduces the clearance of renally eliminated drugs, leading to accumulation and toxicity if doses are not reduced or intervals extended. Furthermore, renal replacement therapy (RRT), such as continuous venovenous hemofiltration (CVVH), adds another layer of complexity, requiring specific dosing strategies based on the modality and effluent rate.
Clinical Scenario
A 28-year-old male is admitted to the trauma ICU following a severe motor vehicle collision. He has received 6 liters of crystalloid resuscitation and is on a norepinephrine infusion. He develops ventilator-associated pneumonia and is prescribed intravenous cefepime (a hydrophilic, renally cleared beta-lactam).
PK Considerations:
Vd: Massive fluid resuscitation and trauma-induced systemic inflammation increase his extracellular fluid volume. Cefepime's Vd is significantly expanded, necessitating a higher initial loading dose to reach target concentrations.
Clearance: Being young and having experienced major trauma, he is at high risk for ARC. If his CrCl is > 130 mL/min, standard cefepime dosing will likely lead to subtherapeutic levels. Aggressive dosing, potentially using an extended or continuous infusion, is required to maintain drug levels above the minimum inhibitory concentration (MIC).
Absorption: Due to shock and vasopressor use, any enterally administered medications would have unpredictable absorption; hence, IV cefepime is the correct route.
Understanding these dynamic PK changes is crucial for optimizing drug efficacy and minimizing toxicity in the critically ill.